{"transactions":[{"id":1950160,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":115482,"kind":"person","name":"Kelemen Vicki","position":1,"cik":"0001815809","reported_name":"Kelemen Vicki","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. VP and COO"}}],"security":"Stock Options","published_at":"2023-03-16T17:41:54.000Z","date":"2023-03-15","kind":"grant","acquired":true,"shares":125520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option will vest on March 15, 2024 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person."}],"balance_after":698304,"derivative":{"exercise_price":1.72,"expiration_date":"2033-03-15","underlying":"Common Stock","underlying_shares":125520},"source":{"system":"sec-edgar","filing":"0001628280-23-008355","document":"wf-form4_167900290271838.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815809/000162828023008355/wf-form4_167900290271838.xml","form_type":"4"}},{"id":2340033,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":115482,"kind":"person","name":"Kelemen Vicki","position":1,"cik":"0001815809","reported_name":"Kelemen Vicki","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. VP and COO"}}],"security":"Stock Options","published_at":"2022-03-10T18:40:11.000Z","date":"2022-03-09","kind":"grant","acquired":true,"shares":170016,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"42,504 vest on 3/09/2023. 3,542 vest monthly for 36 months beginning on 4/09/2023 through 3/09/2026."}],"balance_after":572784,"derivative":{"exercise_price":2.5,"expiration_date":"2032-03-09","underlying":"Common Stock","underlying_shares":170016},"source":{"system":"sec-edgar","filing":"0001628280-22-005791","document":"wf-form4_164695558683169.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815809/000162828022005791/wf-form4_164695558683169.xml","form_type":"4"}},{"id":2670395,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":115482,"kind":"person","name":"Kelemen Vicki","position":1,"cik":"0001815809","reported_name":"Kelemen Vicki","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. VP and COO"}}],"security":"Stock Options","published_at":"2021-06-14T16:12:09.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":200928,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"50,232 vest on 6/10/2022. 4,186 vest monthly for 36 months beginning on 7/10/2022 through 6/10/2025."}],"balance_after":402768,"derivative":{"exercise_price":7.98,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":200928},"source":{"system":"sec-edgar","filing":"0001628280-21-012173","document":"wf-form4_162370151060627.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815809/000162828021012173/wf-form4_162370151060627.xml","form_type":"4"}},{"id":2775055,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":115482,"kind":"person","name":"Kelemen Vicki","position":1,"cik":"0001815809","reported_name":"Kelemen Vicki","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. VP and COO"}}],"security":"Common Stock","published_at":"2021-03-23T14:30:32.000Z","date":"2021-03-23","kind":"purchase","acquired":true,"shares":960,"price":10.31,"value":9897.6,"ownership":{"direct":true},"balance_after":6053,"source":{"system":"sec-edgar","filing":"0001628280-21-005343","document":"wf-form4_161652421851684.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815809/000162828021005343/wf-form4_161652421851684.xml","form_type":"4"}},{"id":2921459,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":115482,"kind":"person","name":"Kelemen Vicki","position":1,"cik":"0001815809","reported_name":"Kelemen Vicki","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. VP and COO"}}],"security":"Restricted Stock Units","published_at":"2021-01-05T16:04:03.000Z","date":"2021-01-02","kind":"exercise","acquired":false,"shares":70,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit is the economic equivalent of one share of Cardiff Oncology, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 4, 2017, the reporting person was granted 278 restricted stock units, 70 of which vested on January 2, 2021. The common stock into which such vested restricted stock units converted on January 2, 2021 is reported in Table I on this Form 4."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 4, 2017, the reporting person was granted 278 restricted stock units, 70 of which vested on January 2, 2021. The common stock into which such vested restricted stock units converted on January 2, 2021 is reported in Table I on this Form 4."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":70},"source":{"system":"sec-edgar","filing":"0001628280-21-000061","document":"wf-form4_160988062663348.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815809/000162828021000061/wf-form4_160988062663348.xml","form_type":"4"}},{"id":2921458,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":115482,"kind":"person","name":"Kelemen Vicki","position":1,"cik":"0001815809","reported_name":"Kelemen Vicki","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. VP and COO"}}],"security":"Common Stock","published_at":"2021-01-05T16:04:03.000Z","date":"2021-01-02","kind":"tax_withholding","acquired":false,"shares":31,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reporting person is reporting the withholding by Cardiff Oncology, Inc. of 31 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 4, 2021."}],"balance_after":5093,"source":{"system":"sec-edgar","filing":"0001628280-21-000061","document":"wf-form4_160988062663348.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815809/000162828021000061/wf-form4_160988062663348.xml","form_type":"4"}},{"id":2921457,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":115482,"kind":"person","name":"Kelemen Vicki","position":1,"cik":"0001815809","reported_name":"Kelemen Vicki","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. VP and COO"}}],"security":"Common Stock","published_at":"2021-01-05T16:04:03.000Z","date":"2021-01-02","kind":"exercise","acquired":true,"shares":70,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the conversion upon vesting of restricted stock units into common stock (the \"Converted Common Stock\"). On January 4, 2017, the reporting person was granted 1,459 restricted stock units, 261 of which vested on January 2, 2020. Such restricted stock units were previously reported in Table II on a Form 3 filed with the Securities and Exchange Commission on June 22, 2020."}],"balance_after":5124,"source":{"system":"sec-edgar","filing":"0001628280-21-000061","document":"wf-form4_160988062663348.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815809/000162828021000061/wf-form4_160988062663348.xml","form_type":"4"}},{"id":2966375,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":115482,"kind":"person","name":"Kelemen Vicki","position":1,"cik":"0001815809","reported_name":"Kelemen Vicki","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. VP and COO"}}],"security":"Stock Options","published_at":"2020-11-25T16:02:46.000Z","date":"2020-11-23","kind":"exercise","acquired":false,"shares":35321,"price":2.48,"value":87596.08,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"35,321 options vested on 6/20/2020."}],"balance_after":70641,"derivative":{"exercise_price":2.48,"expiration_date":"2029-06-20","underlying":"Common Stock","underlying_shares":35321},"source":{"system":"sec-edgar","filing":"0001628280-20-016822","document":"wf-form4_160633815218613.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815809/000162828020016822/wf-form4_160633815218613.xml","form_type":"4"}},{"id":2966374,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":115482,"kind":"person","name":"Kelemen Vicki","position":1,"cik":"0001815809","reported_name":"Kelemen Vicki","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. VP and COO"}}],"security":"Common Stock","published_at":"2020-11-25T16:02:46.000Z","date":"2020-11-23","kind":"sale","acquired":false,"shares":35321,"price":18.6014,"value":657020.0494,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock was sold by the reporting person in a series of open market transactions on the transaction date at a weighted average sale price of $18.6014. The range of prices was $18.40 to $19.25. The reporting person undertakes to provide upon request by the SEC staff, the issuer, or a securityholder of the issuer, full information regarding the number of shares sold at each price."}],"balance_after":5054,"source":{"system":"sec-edgar","filing":"0001628280-20-016822","document":"wf-form4_160633815218613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815809/000162828020016822/wf-form4_160633815218613.xml","form_type":"4"}},{"id":2966373,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":115482,"kind":"person","name":"Kelemen Vicki","position":1,"cik":"0001815809","reported_name":"Kelemen Vicki","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. VP and COO"}}],"security":"Common Stock","published_at":"2020-11-25T16:02:46.000Z","date":"2020-11-23","kind":"exercise","acquired":true,"shares":35321,"price":2.48,"value":87596.08,"ownership":{"direct":true},"balance_after":40375,"source":{"system":"sec-edgar","filing":"0001628280-20-016822","document":"wf-form4_160633815218613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815809/000162828020016822/wf-form4_160633815218613.xml","form_type":"4"}}]}